Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIMELVax in advanced melanoma
NCT06556004Phase 1Unknown
- Sponsor
- Universidad de Chile
- Start
- May 2021
- Primary completion
- Dec 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TRIMELVax in melanoma, sponsored by Universidad de Chile. Primary endpoint: Safety of treatment at 1 year. Status: unknown.
02
Drugs
TRIMELVax
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06556004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06556004.